Baldwin Brothers LLC Editas Medicine, Inc. Transaction History

Baldwin Brothers LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 12, 2024	BUY	$4.67 - $7.28 $37 - $58	8 New	8 $0
Q1 2022 Apr 13, 2022	BUY	$14.08 - $27.63 $2,534 - $4,973	180 Added 127.66%	321 $6,000
Q3 2021 Oct 27, 2021	BUY	$39.27 - $72.94 $824 - $1,531	21 Added 17.5%	141 $6,000
Q4 2019 Jan 29, 2020	SELL	$19.49 - $32.63 $974 - $1,631	-50 Reduced 29.41%	120 $4,000
Q4 2018 Feb 01, 2019	BUY	$18.19 - $31.79 $3,092 - $5,404	170 New	170 $4,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Baldwin Brothers LLC, based on Form 13F filings with the SEC.

Stay updated on Baldwin Brothers LLC with notifications on news.